Treatment Outcomes and Clinicopathologic Characteristics of Advanced Her-2 Positive Breast Cancer Patients
-
摘要: 目的 分析晚期Her-2受体阳性乳腺癌的临床特征，探讨影响其预后的因素。方法收集本院2002年1月—2008年12月间114例晚期Her-2阳性乳腺癌患者的临床资料，回顾性研究其临床特点、生存状况及预后因素。结果114例晚期Her-2阳性乳腺癌患者中位年龄为46岁，8例为初治Ⅳ期;106例为初治Ⅰ~Ⅲ期，术后出现局部复发或远处转移。随访至2011年8月15日，死亡58例（51.0%）。单因素预后分析结果显示，复发年龄、是否绝经、复发转移后是否接受化疗及一线化疗疗效对患者的OS有显著影响（P<0.05）。Cox比例风险模型分析结果显示，复发年龄、是否接受一线化疗以及一线化疗疗效是影响晚期Her-2高表达乳腺癌预后的独立因素。结论晚期Her-2高表达乳腺癌患者早期易出现局部复发和远处转移,可能与其侵袭性较高有关。晚期Her-2高表达乳腺癌患者化疗能够改善其预后。Abstract: Objective To characterize the sites of distant recurrence and clinical outcomes in a cohort of Chinese patients with metastatic Her-2 positive breast cancer. Methods One hundred and fourteen patients with metastatic Her-2 positive breast cancer treated at Shandong Tumor Hospital from January 2002 to December 2008 were included in this study.The clinicopathologic features and long-term survival of the patients were retrospectively analyzed. Results The median age of the patients was 46 years.8 patients presented with stage Ⅳdisease,106 patients presented withⅠ- Ⅲ stage.By August 15th,2011,58 patients were died(51.0%).The median OS of patients with CR/PR was significantly longer than that of patients with SD/PD.Distant metastasis,first-line chemotherapy and clinical response were signi ficantly related with OS by univariate analysis.Furthermore,first-line chemotherapy and clinical response were demonstrated to be independent prognostic factor by multivariate analysis. Conclusion Recurrence risk and mortality are considerably higher in advanced Her-2 overexpressed breast cancer patients with the early years follow-up.Advanced Her-2 overexpressed breast cancer is aggressive clinical behavior.Our findings also suggest that chemotherapy can effectively improve the outcome of those patients.
-
Key words:
- Breast neoplasms /
- Prognosis /
- Drug therapy /
- Combination
-
-
[1] Dent S,Verma Sh,Latreille J,et al.The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer[J].Curr Oncol,2009,16(4):25-35. [2] Witton CJ,Reeves JR,Going JJ,et al.Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer[J].J Pathol,2003,200(3):290-7. [3] Wiechmann L,Sampson M,Stempel M,et al.Presenting features of breast cancer differ by molecular subtype[J].Ann Surg Oncol,2009,16(10):2705-10. [4] Gabos Z,Thoms J,Ghosh S,et al.The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer[J].Breast Cancer Res Treat,2010,124(1):187-94. [5] Koo JS,Jung W,Shin E,et al.Impact of grade,hormone receptor,and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay[ J].J Korean Med Sci,2009,24(6):1150-7. [6] Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-92. [7] Saad ED,Katz A,Buyse M.Overall survival and post-progression survival in advanced breast cancer:a review of recent randomized clinical trials[J].J Clin Oncol,2010,28(11):1958-62. [8] Lee CK,Hudson M,Stockler M,et al.A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer[J].Breast Cancer Res Treat,2011,129(2):467-76.
计量
- 文章访问数: 2063
- HTML全文浏览量: 26
- PDF下载量: 689
下载:
